Studying why some chronic lymphocytic leukemia patients respond to BTK degraders
Collects blood samples to study resistance to BTK degraders in leukemia.
Plain-language title generated from the registry record
Registry title: Determinants of the Response to BTK Degraders (BTKd) in Chronic Lymphocytic Leukemia
Key facts
- Where
- Angers, Bordeaux, Clermont-Ferrand, La Roche-sur-Yon, Lyon, Marseille, Montpellier, Nancy, Nantes, Paris, Poitiers, and Rouen, FranceSee the 14 sites
Where in France
- CHU de AngersAngers, FranceNot yet recruiting
- CHU de BordeauxBordeaux, FranceNot yet recruiting
- Institut BergonieBordeaux, FranceNot yet recruiting
- CHU de Clermont-FerrandClermont-Ferrand, FranceNot yet recruiting
- CHD VendéeLa Roche-sur-Yon, FranceTaking people
- Centre Léon BernardLyon, FranceNot yet recruiting
- Institut Paoli Calmettes (Marseille)Marseille, FranceNot yet recruiting
- CHU de MontpellierMontpellier, FranceNot yet recruiting
- CH Régional Universitaire de NancyNancy, FranceNot yet recruiting
- University HospitalNantes, FranceTaking people
- Hôpital Avicenne (AP-HP)Paris, FranceNot yet recruiting
- Hôpital Universitaire Pitié Salpêtrière de ParisParis, FranceNot yet recruiting
- CHU de PoitiersPoitiers, FranceNot yet recruiting
- Centre Henri-Becquerel de RouenRouen, FranceNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Nantes University Hospital
- Trial code
- NCT07099443
- Record updated
- 8 July 2026
- Original description
The aim of the REBELLE cohort - bio-collection is to collect samples from patients with Chronic Lymphocytic Leukemia candidates or those exposed to BTK degraders to evaluate the mechanisms of resistance to these new molecules. To do this, an additional blood or bone marrow sample to those planned in the context of patient care or a residual lymph node biopsy sample will be collected after signing consent.Read full original descriptionShow less
Determinants of the Response to BTK Degraders (BTKd) in Chronic Lymphocytic Leukemia
The aim of the REBELLE cohort - bio-collection is to collect samples from patients with Chronic Lymphocytic Leukemia candidates or those exposed to BTK degraders to evaluate the mechanisms of resistance to these new molecules. To do this, an additional blood or bone marrow sample to those planned in the context of patient care or a residual lymph node biopsy sample will be collected after signing consent.
Inclusion: Patient with CLL candidates ou exposed to BTKd; Patient who has provided informed consent to participate in the study; Patient covered by a social security health insurance plan.
Exclusion: Minor patients; Adults under guardianship; Protected persons.